Some users prefer evening injection for practical reasons or because early nausea effects are easier to manage during sleep
Semaglutide, a GLP-1 receptor agonist, is known for its ability to help suppress appetite and support healthy weight loss

Semaglutide May Be Best For: Individuals who want a well-studied, FDA-approved medication with extensive long-term safety data Patients who prioritize cardiovascular risk reduction (supported by the SELECT trial) People seeking a medication with established insurance coverage pathways Individuals with moderate weight loss goals (10-15% of body weight) Patients who value the reassurance of a medication used by millions of people worldwide Retatrutide May Be Best For (Once Available): Individuals who need greater than 15-20% body weight loss Patients who have plateaued on semaglutide or tirzepatide People with significant metabolic dysfunction who may benefit from the glucagon receptors effects on liver fat and energy expenditure Individuals with MASH (metabolic dysfunction-associated steatohepatitis) given the glucagon receptors role in hepatic fat metabolism Patients willing to use a newer medication with less long-term safety data in exchange for potentially greater efficacy What to Expect During Treatment Starting Semaglutide Weeks 1-4: Starting dose of 0.25 mg weekly

And that fourth pathway, the amylin system, does not just add incremental benefit
The trial data show that stopping often leads to regain, which is why the decision should be made with your provider based on your goals and health (STEP 1 extension, PMC)
RetatrutideGuide.org The Definitive Triple-Agonist Research ResourceWhere to Buy Retatrutide (GLP3-R) in 2026Retatrutide (LY3437943) is the first-in-class GLP-1/GIP/GCGR triple-agonist